Researchers therefore evaluated the effectiveness and safety of topical finasteride 0.25% monotherapy over 1 year in a real-world clinical setting. Researchers reviewed the medical records of 123 adult men with AGA who had received topical finasteride 0.25% monotherapy between April 2022 and November 2025. Improvements in Hair Number and ThicknessAfter 52 weeks of topical finasteride, total hair number increased significantly in both the vertex and temporal regions. Topical Finasteride Was Well ToleratedTopical finasteride 0.25% was generally well tolerated during the 52-week treatment period. Long-term effectiveness and safety of topical finasteride 0.25% monotherapy in male androgenetic alopecia: a 52-week real-world retrospective study.